Lilly/BI 'biosimilar Lantus' filed in Europe
This article was originally published in Scrip
Executive Summary
Eli Lilly and and Boehringer Ingelheim have had their marketing authorization application (MAA) for the biosimilar LY2963016, a basal (long-acting) insulin analog for the treatment of type 1 and type 2 diabetes, accepted for review by the European Medicines Agency. LY2963016 is a new insulin glargine product and was filed through the EMA's biosimilar pathway.
You may also be interested in...
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Pfizer/Astellas Amend Trial To Position Xtandi In Early Prostate Cancer
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.